Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Budman

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
Cancer Investigation|January 1, 1996
Clinical pharmacokinetics of amonafide (NSC 308847) in 62 patientsW Kreis, K Chan, D R Budman, et al.
Investigational New Drugs|August 1, 1990
Phase I trial of intravenous vinzolidine (LY 104208) given on a biweekly dosing scheduleD R Budman, W Kreis, J Behr, et al.
American Journal of Clinical Oncology|July 28, 2001
Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, Novantrone (mitoxantrone), vincristine, prednisone (TNOP)S M Lichtman, J Kolitz, D R Budman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabineD R Budman, N J Meropol, B Reigner, et al.
Annals of Internal Medicine|December 1, 1978
Increased risk of lymphoma in sicca syndromeS S Kassan, T L Thomas, H M Moutsopoulos, et al.
Cancer Chemotherapy and Pharmacology|July 19, 2001
Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesisD R Budman, R Johnson, B Barile, et al.
Leukemia|May 1, 1991
Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB StudyJ Cuttner, R Mick, D R Budman, et al.
Journal of the National Cancer Institute|August 18, 1993
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B studyS M Lichtman, M J Ratain, D A Van Echo, et al.
The New England Journal of Medicine|May 5, 1994
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancerH B Muss, A D Thor, D A Berry, et al.
Bone Marrow Transplantation|November 1, 1996
Phase I study of high-dose etoposide phosphate in manS Z Fields, D R Budman, R R Young, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
Cancer Investigation|January 1, 1996
Clinical pharmacokinetics of amonafide (NSC 308847) in 62 patientsW Kreis, K Chan, D R Budman, et al.
Investigational New Drugs|August 1, 1990
Phase I trial of intravenous vinzolidine (LY 104208) given on a biweekly dosing scheduleD R Budman, W Kreis, J Behr, et al.
American Journal of Clinical Oncology|July 28, 2001
Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, Novantrone (mitoxantrone), vincristine, prednisone (TNOP)S M Lichtman, J Kolitz, D R Budman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabineD R Budman, N J Meropol, B Reigner, et al.
Annals of Internal Medicine|December 1, 1978
Increased risk of lymphoma in sicca syndromeS S Kassan, T L Thomas, H M Moutsopoulos, et al.
Cancer Chemotherapy and Pharmacology|July 19, 2001
Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesisD R Budman, R Johnson, B Barile, et al.
Leukemia|May 1, 1991
Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB StudyJ Cuttner, R Mick, D R Budman, et al.
Journal of the National Cancer Institute|August 18, 1993
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B studyS M Lichtman, M J Ratain, D A Van Echo, et al.
The New England Journal of Medicine|May 5, 1994
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancerH B Muss, A D Thor, D A Berry, et al.
Bone Marrow Transplantation|November 1, 1996
Phase I study of high-dose etoposide phosphate in manS Z Fields, D R Budman, R R Young, et al.
Pageof 11